Author

Sarita Rajender Potlapally

Observed names: Potlapally Sarita Rajender, Potlapally, Sarita Rajender, S. R. Potlapally

Institution: Osmania University

Observed institution: Osmania University

ORCID: 0000-0002-6453-9705

Observed ORCID: 0000-0002-6453-9705

OpenAlex ID: A5001504766

Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach

2017 · Rohini Rondla, Lavanya Souda PadmaRao, et al. · Computational Biology and Chemistry · 30

Homology modeling and virtual screening of ubiquitin conjugation enzyme E2A for designing a novel selective antagonist against cancer

2014 · Vishwanath Ramatenki, Sarita Rajender Potlapally, et al. · Journal of Receptors and Signal Transduction · 30

Structure-based identification of potential novel inhibitors targeting FAM3B (PANDER) causing type 2 diabetes mellitus through virtual screening

2019 · Goverdhan Lanka, Revanth Bathula, et al. · Journal of Receptors and Signal Transduction · 24

Identification of potential Aurora kinase-C protein inhibitors: an amalgamation of energy minimization, virtual screening, prime MMGBSA and AutoDock

2019 · Revanth Bathula, Goverdhan Lanka, et al. · Journal of Biomolecular Structure and Dynamics · 22

Identification of novel anti cancer agents by applying insilico methods for inhibition of TSPO protein

2017 · Manan Bhargavi, Sree Kanth Sivan, et al. · Computational Biology and Chemistry · 21

Identification of novel leads applyingin silicostudies for Mycobacterium multidrug resistant (MMR) protein

2013 · Vasavi Malkhed, Kiran Kumar Mustyala, et al. · Journal of Biomolecular Structure and Dynamics · 21

Azolium analogues as CDK4 inhibitors: Pharmacophore modeling, 3D QSAR study and new lead drug discovery

2017 · Rohini Rondla, Lavanya Souda Padma Rao, et al. · Journal of Molecular Structure · 17

Identification of New Lead Molecules Against UBE2NL Enzyme for Cancer Therapy

2017 · Vishwanath Ramatenki, Ramakrishna Dumpati, et al. · Applied Biochemistry and Biotechnology · 14

Targeting the ubiquitin-conjugating enzyme E2D4 for cancer drug discovery–a structure-based approach

2016 · Vishwanath Ramatenki, Ramakrishna Dumpati, et al. · Journal of Chemical Biology · 13

Identification of new anti-cancer agents against CENTERIN: Structure-based virtual screening, AutoDock and binding free energy studies

2022 · Sravanthi Nakkala, Chandrima Modak, et al. · Journal of Molecular Structure · 11

Modeling of Alternate RNA Polymerase Sigma D Factor and Identification of Novel Inhibitors by Virtual Screening

2012 · Vasavi Malkhed, Kiran Kumar Mustyala, et al. · Cellular and Molecular Bioengineering · 10

Understanding structural characteristics of PARP-1 inhibitors through combined 3D-QSAR and molecular docking studies and discovery of new inhibitors by multistage virtual screening

2021 · Pagadala Revathi, Sivan Sree Kanth, et al. · Structural Chemistry · 9

Homology modelling and virtual screening to explore potent inhibitors for MAP2K3 protein

2020 · Manan Bhargavi, Nazmina Vhora, et al. · Structural Chemistry · 9

Macromolecular structure and interaction studies of SigF and Usfx inMycobacterium tuberculosis

2014 · Kiran Kumar Mustyala, Vasavi Malkhed, et al. · Journal of Receptors and Signal Transduction · 9

Targeting tribbles homolog 3 (TRIB3) protein against type 2 diabetes for the identification of potential inhibitors by in silico screening

2022 · Goverdhan Lanka, Manan Bhargavi, et al. · Journal of the Indian Chemical Society · 8

Identification of potential antiviral lead inhibitors against SARS-CoV-2 main protease: Structure-guided virtual screening, docking, ADME, and MD Simulation based approach

2023 · Goverdhan Lanka, Revanth Bathula, et al. · Artificial Intelligence Chemistry · 7

Tin ( IV ) chloride catalyzed one‐pot synthesis, characterization, and docking studies of 4‐aminoquinoline derivatives as Myt1 inhibitors

2022 · Narasimha Muddagoni, Mahendar Dasari, et al. · Journal of Heterocyclic Chemistry · 5

Identification and optimisation of novel selective inhibitors against human regulator of G protein signalling 2 (RGS2) protein for type 2 diabetes mellitus: an in silico approach

2021 · Manan Bhargavi, Sarita Rajender Potlapally, et al. · International Journal of Computational Biology and Drug Design · 5

Homology modeling and molecular docking studies for the identification of novel potential therapeutics against human PHD3 as a drug target for type 2 diabetes mellitus

2019 · Goverdhan Lanka, Revanth Bathula, et al. · Journal of Drug Delivery and Therapeutics · 5

PDF

Synthesis and Molecular Docking Study of Novel Pyrazole-Integrated 1,3,4-Oxadiazole Derivatives as Potential Cyclin-Dependent Kinase 2 Inhibitors

2023 · R. Bathula, N. Muddagoni, et al. · Russian Journal of Organic Chemistry · 3

Structural insight into PRMT5 inhibitors through amalgamating pharmacophore-based virtual screening, ADME toxicity, and binding energy studies to identify new inhibitors by molecular docking

2022 · Revanth Bathula, Goverdhan Lanka, et al. · Structural Chemistry · 3

PDF

Synthesis, In Silico Studies, and In Vitro Evaluation of Pyridine-Enriched 1,2,3-Triazole Scaffolds Against the Blood Cancer K562 Cell Line

2026 · Palreddy Reshma, Revanth Bathula, et al. · Polycyclic aromatic compounds

Synthesis, In Silico Studies, and In Vitro Evaluation of Pyridine-Enriched 1,2,3-Triazole Scaffolds Against the Blood Cancer K562 Cell Line

2026 · Palreddy Reshma, Revanth Bathula, et al. · Figshare

Rational design of Ticagrelor-inspired sulfonamide analogues targeting EGFR protein: an integrated experimental and computational study

2026 · Manan Bhargavi, Priyanka Devi, et al. · Journal of Molecular Structure

Works count: 25

Citation count: 276

H-index: 10

I10-index: 11